Autres langues China SXT Pharmaceuticals, Inc.

Actions

SXTC

VGG2161P1734

Produits pharmaceutiques

Temps Différé Nasdaq 16:16:53 14/09/2026			Varia. 5j.	Varia. 1 janv.
2,510 ^USD	-1,95%		+12,05%	-99,99%

05/08	Les plus fortes baisses en avant-Bourse	MT
30/07	Les plus fortes hausses en pré-séance	MT

Autres langues

05/08	China SXT Pharmaceuticals, Inc. Announces Share Consolidation
05/08	Top Premarket Decliners
30/07	Top Premarket Gainers
28/07	Top Premarket Decliners
24/07	Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
24/07	Top Premarket Decliners
23/07	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
23/07	Top Premarket Decliners
22/07	Top Premarket Gainers
03/07	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding
01/07	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
01/07	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026
24/03	China SXT Pharmaceuticals, Inc. Announces Share Re-classification
30/01	China SXT Pharmaceuticals, Inc. Announces Share Consolidation
15/01	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
13/01	Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
09/01	China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
08/01	Top Midday Gainers
08/01	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
31/12	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025
31/07/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025
28/03/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024
17/03/25	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement
17/03/25	China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency
21/02/25	China SXT Pharmaceuticals, Inc. Announces Share Consolidation